Cirius Therapeutics
Bob Baltera is an accomplished executive in the biotechnology sector, currently serving as a Board Member for Imago BioSciences, Inc. and Inipharm, since April 2020 and July 2019, respectively. Baltera has held the position of CEO at Cirius Therapeutics since April 2017, following prior leadership roles as CEO at Hawkeye Therapeutics and Laguna Pharmaceuticals between January 2016 and December 2015, and at Amira Pharmaceuticals from July 2007 to September 2011. Additionally, Baltera served on the Board of Directors for Organovo Holdings, Inc. from September 2010 to September 2019. Prior to these roles, Baltera was Vice President at Amgen for 17 years, from November 1990 to July 2007. Educationally, Baltera earned a Master's degree in Genetics from Penn State University and a Bachelor's degree in Microbiology from the same institution, in addition to completing a program at the UCLA Anderson School of Management.
This person is not in any offices
Cirius Therapeutics
Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novelinsulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH.Circius Therapeutics focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States.